DiaSorin S.p.A. (LON:0GZX)

Market Cap	3.63B
Revenue (ttm)	1.04B
Net Income (ttm)	164.15M
Shares Out	n/a
EPS (ttm)	2.93
PE Ratio	22.13
Forward PE	16.47
Dividend	1.01 (1.30%)
Ex-Dividend Date	May 19, 2025

Volume	11,934
Average Volume	70,956
Open	78.74
Previous Close	78.66
Day's Range	77.94 - 78.64
52-Week Range	73.06 - 112.10
Beta	0.32
RSI	44.36
Earnings Date	Nov 5, 2025

About DiaSorin

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urin...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,308
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GZX

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.

Financial numbers in EUR